Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Vistagen Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 34 | 46 | +12 |
| Shares | 3.00M | 17.6M | +14.6M (+485.5%) |
| Value | $15.7M | $90.0M | +$74.2M (+471.7%) |
New holders (24)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (12)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Ikarian Capital, LLC | 229,100 | $1.20M |
| Schonfeld Strategic Advisors LLC | 138,500 | $725.7K |
| Group One Trading, L.P. | 75,305 | $394.6K |
| MYDA Advisors LLC | 50,000 | $262.0K |
| Boothbay Fund Management, LLC | 46,895 | $245.7K |
| Gsa Capital Partners LLP | 46,782 | $245.0K |
| Prelude Capital Management, LLC | 20,200 | $105.8K |
| Susquehanna International Group, LLP | 19,355 | $101.4K |
| Millennium Management LLC | 16,870 | $88.4K |
| Raymond James & Associates | 10,000 | $52.4K |
| Qube Research & Technologies Ltd | 1,192 | $6.25K |
| Toronto Dominion Bank | 46 | $241 |